Philip Vlummens
Overview
Explore the profile of Philip Vlummens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
613
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Den Berghe T, Verberckmoes B, Kint N, Wallaert S, De Vos N, Algoet C, et al.
Insights Imaging
. 2024 Apr;
15(1):106.
PMID: 38597979
Objectives: Cytogenetic abnormalities are predictors of poor prognosis in multiple myeloma (MM). This paper aims to build and validate a multiparametric conventional and functional whole-body MRI-based prediction model for cytogenetic...
2.
Clarisse D, Prekovic S, Vlummens P, Staessens E, Van Wesemael K, Thommis J, et al.
Cell Mol Life Sci
. 2023 Aug;
80(9):249.
PMID: 37578563
The glucocorticoid receptor (GR) is a crucial drug target in multiple myeloma as its activation with glucocorticoids effectively triggers myeloma cell death. However, as high-dose glucocorticoids are also associated with...
3.
Wang Y, Muylaert C, Wyns A, Vlummens P, de Veirman K, Vanderkerken K, et al.
Haematologica
. 2023 Jul;
109(1):256-271.
PMID: 37470139
Multiple myeloma (MM) is the second most prevalent hematologic malignancy and is incurable because of the inevitable development of drug resistance. Methionine adenosyltransferase 2α (MAT2A) is the primary producer of...
4.
Van der Vreken A, Oudaert I, Ates G, Faict S, Vlummens P, Satilmis H, et al.
J Pathol
. 2023 Feb;
260(2):112-123.
PMID: 36807305
Multiple myeloma (MM) remains an incurable haematological malignancy despite substantial advances in therapy. Hypoxic bone marrow induces metabolic rewiring in MM cells contributing to survival and drug resistance. Therefore, targeting...
5.
Fan R, Satilmis H, Vandewalle N, Verheye E, Vlummens P, Maes A, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36650020
Background: Immunotherapy emerged as a promising treatment option for multiple myeloma (MM) patients. However, therapeutic efficacy can be hampered by the presence of an immunosuppressive bone marrow microenvironment including myeloid...
6.
Satilmis H, Verheye E, Vlummens P, Oudaert I, Vandewalle N, Fan R, et al.
J Pathol
. 2022 Oct;
259(1):69-80.
PMID: 36245401
While multi-drug combinations and continuous treatment have become standard for multiple myeloma, the disease remains incurable. Repurposing drugs that are currently used for other indications could provide a novel approach...
7.
Vlummens P, Verhulst S, de Veirman K, Maes A, Menu E, Moreaux J, et al.
Front Cell Dev Biol
. 2022 Jun;
10:879057.
PMID: 35757005
Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. Subsets of patients have high-risk features linked with dismal outcome. Therefore, the need for effective therapeutic options remains high. Here,...
8.
Wang F, Oudaert I, Tu C, Maes A, Van der Vreken A, Vlummens P, et al.
Cancer Lett
. 2022 Mar;
535:215649.
PMID: 35315341
Multiple myeloma (MM) cells derive proliferative signals from the bone marrow (BM) microenvironment via exosomal crosstalk. Therapeutic strategies targeting this crosstalk are still lacking. Bortezomib resistance in MM cells is...
9.
Oudaert I, Satilmis H, Vlummens P, De Brouwer W, Maes A, Hose D, et al.
J Exp Clin Cancer Res
. 2022 Feb;
41(1):45.
PMID: 35105345
Background: Multiple myeloma (MM) remains an incurable cancer despite advances in therapy. Therefore, the search for new targets is still essential to uncover potential treatment strategies. Metabolic changes, induced by...
10.
Brieghel C, Galle V, Agius R, da Cunha-Bang C, Andersen M, Vlummens P, et al.
Eur J Haematol
. 2022 Jan;
108(5):369-378.
PMID: 35030282
Introduction: Early-stage chronic lymphocytic leukemia (CLL) challenges specialized management and follow-up. Methods: We developed and validated a prognostic index to identify newly diagnosed patients without need of treatment (CLL-WONT) by...